Kooperativer Bibliotheksverbund

UID:

Umfang: 1 online resource (496 pages)

ISBN: 0-12-822626-9

Serie: Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy ; v.Volume 4

Inhalt: NK Cells in Cancer Immunotherapy: Successes and Challenges explains the latest immunotherapeutic strategies, focusing on NK cells to allow the best and precise combination treatments to cancer patients. The book provides existing background knowledge in the field of immunotherapy and discusses future areas of research required to carry out cutting-edge, validated therapies. Chapters cover advances in immunotherapeutic strategies, in particular, the use of NK cells with and without T-cell therapy in the treatment of cancer. The book is a valuable resource for cancer researchers, oncologists, graduate students and those interested in learning more about novel strategies to treat cancer patients.

Anmerkung: Intro -- NK Cells in Cancer Immunotherapy: Successes and Challenges -- Copyright -- Cover Image Insert -- Hypothetical role of NK cells in differentiation of tumor cells, increased susceptibility of tumor cells to chemotherapy or ... -- Aims and Scope of Series ``Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy´´ -- About the Series Editor -- Aims and Scope of Volume -- About the Volume Editors -- Preface-Cellular immunotherapies: Evolution from laboratory studies to effective human therapies -- Contents -- Contributors -- Section I: Basics of cellular immunotherapy: Differing roles of NK and T cells in targeting cancer and their intimate syn ... -- Chapter 1: Multifaceted nature of natural killer cells: Potential mode of interaction and shaping of stem cells -- Natural killer cells: Overview and background -- Two faces of NK cells: Concept of split anergy in NK cells and its potential role in tumor differentiation -- The rationale for the functional activation of NK cells in many gene knockout mice: Potential common mechanism of activation -- Dysfunctional NK cells in cancer patients: Defects in NK cells to lyse and differentiate CSCs -- Suppression of antitumor immune function and change in NK cell phenotype in tumor microenvironment: Could compromised NK fu ... -- Tumor-associated stromal cells may shape the function of NK cells -- Function of NK cells in tumor-bearing humanized-BLT mice mirrors those of the cancer patients -- Novel strategy to expand supercharged NK cells for immunotherapy using osteoclasts as feeder cells: Different efficacy of s ... -- Supercharged NK cells differ from primary NK cells in phenotype and function -- Supercharged NK cells preferentially and rapidly expand CD8+ T cells -- Functional differences of NK cells in different NK expansion platforms against CSCs/poorly differentiated tumor cells: Comp. , Immunotherapy is essential in combination with chemotherapy: Chemotherapy targets differentiated tumors more than cancer st ... -- Combination of NK cell and antibody therapy: NK cells can target CSCs and their differentiated counterparts through direct ... -- NK cells and the oncolytic viruses -- Combination therapy with NK cells and immune checkpoint inhibitors -- Conclusions -- Acknowledgments -- References -- Chapter 2: Reversing the NK inhibitory tumor microenvironment by targeting suppressive immune effectors -- Introduction -- Dysregulation of NK cell immune responses by the tumor microenvironment -- Suppressive immune effectors of the tumor microenvironment -- Myeloid-derived suppressor cells -- Tumor-associated macrophages -- Regulatory T cells -- Dendritic cells -- Techniques to evaluate the tumor microenvironment -- Improvements in tissue analysis and imaging -- Cytometric analysis of TME composition and function -- Estimating TME composition using gene expression data -- Assessing metabolic fitness in the TME -- Advancements in therapeutic modalities to overcome TME suppression -- Direct targeting of inhibitory immune cells of the TME -- Reversing NK cell inhibition by the TME through genetic and nongenetic methods -- Perspectives and conclusions -- References -- Chapter 3: Natural killer cells as immunotherapeutic effectors for solid tumors -- Introduction -- Sources of NK cells for immunotherapy (Table 1) -- Expanding NK cells -- Challenges to NK cell immunotherapy in solid tumors (Table 2) -- CD73-adenosine -- CD155-TIGIT -- NKG2A -- Genetic engineering of NK cells -- Antigen escape and multitargeting CARs -- NK cell engagers -- Conclusions -- References -- Chapter 4: Targeting NKG2D/NKG2D ligand axis for cancer immunotherapy -- Introduction -- NKG2D -- Molecular characteristics and signaling -- NKG2D ligands -- Human NKG2D ligands. , Mouse NKG2D ligands -- Regulation of NKG2D ligands expression -- Transcriptional regulation -- Posttranslational regulation -- NKG2D in antitumor immunity -- NKG2D ligands stimulate tumor immunity -- Human tumors shed NKG2D ligands to evade immune response -- Strategies to harness NKG2D/NKG2DL for cancer immunotherapy -- Targeting MIC shedding to sustain NKG2D immunity -- Conclusions -- References -- Chapter 5: Chimeric antigen receptor-modified cells for the treatment of solid tumors: First steps in a thousand-m -- Introduction -- CAR T-cell therapy experience in solid tumors -- Glioblastoma -- Neuroblastoma -- Lung cancer -- Mesothelioma -- Breast cancer -- Ovarian cancer -- Prostate cancer -- Renal cell carcinoma -- Sarcoma -- Overcoming challenges facing CAR therapy in solid tumors -- Tumor microenvironment -- Nutrient deprivation -- Immunosuppressive substances -- Acidity -- Hypoxia -- Cell-mediated immunosuppression -- Prospects -- Extracellular matrix barrier -- Prospects -- CAR-T cell trafficking -- Prospects -- CAR T-cell persistence -- Prospects -- Target antigens -- Prospects -- Beyond CAR T-cell therapy -- Conclusion -- Acknowledgments -- References -- Chapter 6: Tumor-infiltrating lymphocyte (TIL) therapy -- Introduction -- Cytotoxic T lymphocytes mediate antigen-specific antitumor immunity -- Tumor immune evasion and T cell exhaustion -- Antigen nonspecific T cell immunotherapy approaches -- Adoptive cell therapy with autologous TILs (TIL ACT) -- Alteration of the immune tumor microenvironment to improves the engraftment of autologous TILs -- Improving antitumor efficacy of TIL ACT by targeting neoantigens -- Impact of cellular phenotype upon TIL ACT longevity -- Improvement in TIL manufacturing and modern-day clinical trials -- TILs and solid tumors other than melanoma -- Summary -- Acknowledgments -- References. , Chapter 7: Biology and status of chimeric antigen receptor-engineered T cell therapy -- Introduction -- Generations of CAR T cells -- FDA approved CAR T cells in hematologic malignancies -- Challenges in solid tumor targeting with CAR T cell therapy -- Physical and metabolic barriers in the solid tumor microenvironment -- The immunosuppressive TME -- Solid tumor antigen heterogeneity and antigen escape -- Future perspective of CAR T cell therapy approaches to tackle solid tumors -- References -- Section II: Process and trials optimization: Diagnostics, readouts, route, and production to optimize cell therapy -- Chapter 8: Optimization of production for cell therapies -- Keep the end goal in mind from early stage: Define the target product profile -- Process design: Take a quality by design approach -- Get to the goal: Many decisions to make -- Upstream processing -- Downstream processing -- Filling and cryopreservation -- Understand the analytical needs -- Identify and overcome the distribution, thawing, and dispensing challenges -- Conclusion -- References -- Chapter 9: Lymphodepletion and cellular immunotherapy -- Introduction -- Regimens for lymphodepletion -- Tumor-infiltrating lymphocytes (TILs) -- Chimeric antigen receptor T-cells (CAR-T cells) -- Solid tumors -- Toxicity of lymphodepletion -- Alternatives to lymphodepletion -- Conclusion -- References -- Chapter 10: Imaging the immune cell in immunotherapy -- Imaging objectives from an immunological perspective -- Imaging modalities and labeling strategies for cancer immunotherapy -- Optical imaging (OI) -- Fluorescence imaging (FLI) -- Bioluminescence imaging (BLI) -- Considerations for optical imaging -- Ultrasound imaging (US) -- Encapsulated gas microbubbles -- Nonmicrobubble contrast agents -- Considerations for ultrasound imaging -- Magnetic resonance imaging (MRI). , Negative contrast agents -- Nuclear-based imaging -- Basic principles of direct labeling -- Considerations for direct labeling -- Basic principles of indirect labeling with reporter genes -- Considerations for indirect labeling -- Application of the ``Imaging Toolbox´´ toward cancer immunotherapy -- Imaging T cell trafficking and persistence -- Imaging cytolytic T cells (CTLs) -- Imaging chimeric antigen receptor T (CAR-T) cells -- Imaging T cell activation -- Direct imaging T cell activation biomarkers -- Direct imaging of targets related to T cell activation and effector function -- Indirect imaging NFAT-mediated T cell activation -- Imaging metabolic targets -- Imaging the tumor microenvironment (TME) -- Imaging of programmed cell death protein 1 (PD-1/CD279) -- Imaging of programmed cell death protein ligand 1 (PD-L1/CD274) -- Imaging of cytotoxic T lymphocyte-associated protein 4 (CTLA-4/CD152) -- Imaging of lymphocyte activation gene 3 protein (LAG3) -- Imaging of T cell immunoglobulin and mucin domain-containing protein 3 (TIM3) -- Imaging of T cell immunoreceptor with Ig and ITIM domains (TIGIT) -- Imaging regulatory T cells (Tregs) -- Imaging NK cells -- Imaging dendritic cell vaccines -- What the future holds -- Acknowledgments -- References -- Chapter 11: Radiologic assessment of tumor response to immunotherapy and its complications -- Introduction -- Uses of medical imaging in immunotherapy -- Challenges to medical imaging presented by immunotherapy -- Unconventional patterns of response in immunotherapy -- Pseudo progression -- Hyperprogression -- Dissociated response -- Immune-related adverse events -- Immune checkpoint inhibitors -- CAR T cell therapies -- Methods of measurement of tumor response -- Conventional tumor response criteria -- Immune tumor response criteria -- FDG-PET for assessment of CAR T-cell therapy. , Future directions for imaging tumor response to immunotherapy.

Weitere Ausg.: Print version: Jewett, Anahid NK Cells in Cancer Immunotherapy: Successes and Challenges San Diego : Elsevier Science & Technology,c2022 ISBN 9780128226209

Sprache: Englisch

UID:

Umfang: 1 online resource (496 pages)

ISBN: 0-12-822626-9

Serie: Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy ; v.Volume 4

Inhalt: NK Cells in Cancer Immunotherapy: Successes and Challenges explains the latest immunotherapeutic strategies, focusing on NK cells to allow the best and precise combination treatments to cancer patients. The book provides existing background knowledge in the field of immunotherapy and discusses future areas of research required to carry out cutting-edge, validated therapies. Chapters cover advances in immunotherapeutic strategies, in particular, the use of NK cells with and without T-cell therapy in the treatment of cancer. The book is a valuable resource for cancer researchers, oncologists, graduate students and those interested in learning more about novel strategies to treat cancer patients.

Anmerkung: Intro -- NK Cells in Cancer Immunotherapy: Successes and Challenges -- Copyright -- Cover Image Insert -- Hypothetical role of NK cells in differentiation of tumor cells, increased susceptibility of tumor cells to chemotherapy or ... -- Aims and Scope of Series ``Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy´´ -- About the Series Editor -- Aims and Scope of Volume -- About the Volume Editors -- Preface-Cellular immunotherapies: Evolution from laboratory studies to effective human therapies -- Contents -- Contributors -- Section I: Basics of cellular immunotherapy: Differing roles of NK and T cells in targeting cancer and their intimate syn ... -- Chapter 1: Multifaceted nature of natural killer cells: Potential mode of interaction and shaping of stem cells -- Natural killer cells: Overview and background -- Two faces of NK cells: Concept of split anergy in NK cells and its potential role in tumor differentiation -- The rationale for the functional activation of NK cells in many gene knockout mice: Potential common mechanism of activation -- Dysfunctional NK cells in cancer patients: Defects in NK cells to lyse and differentiate CSCs -- Suppression of antitumor immune function and change in NK cell phenotype in tumor microenvironment: Could compromised NK fu ... -- Tumor-associated stromal cells may shape the function of NK cells -- Function of NK cells in tumor-bearing humanized-BLT mice mirrors those of the cancer patients -- Novel strategy to expand supercharged NK cells for immunotherapy using osteoclasts as feeder cells: Different efficacy of s ... -- Supercharged NK cells differ from primary NK cells in phenotype and function -- Supercharged NK cells preferentially and rapidly expand CD8+ T cells -- Functional differences of NK cells in different NK expansion platforms against CSCs/poorly differentiated tumor cells: Comp. , Immunotherapy is essential in combination with chemotherapy: Chemotherapy targets differentiated tumors more than cancer st ... -- Combination of NK cell and antibody therapy: NK cells can target CSCs and their differentiated counterparts through direct ... -- NK cells and the oncolytic viruses -- Combination therapy with NK cells and immune checkpoint inhibitors -- Conclusions -- Acknowledgments -- References -- Chapter 2: Reversing the NK inhibitory tumor microenvironment by targeting suppressive immune effectors -- Introduction -- Dysregulation of NK cell immune responses by the tumor microenvironment -- Suppressive immune effectors of the tumor microenvironment -- Myeloid-derived suppressor cells -- Tumor-associated macrophages -- Regulatory T cells -- Dendritic cells -- Techniques to evaluate the tumor microenvironment -- Improvements in tissue analysis and imaging -- Cytometric analysis of TME composition and function -- Estimating TME composition using gene expression data -- Assessing metabolic fitness in the TME -- Advancements in therapeutic modalities to overcome TME suppression -- Direct targeting of inhibitory immune cells of the TME -- Reversing NK cell inhibition by the TME through genetic and nongenetic methods -- Perspectives and conclusions -- References -- Chapter 3: Natural killer cells as immunotherapeutic effectors for solid tumors -- Introduction -- Sources of NK cells for immunotherapy (Table 1) -- Expanding NK cells -- Challenges to NK cell immunotherapy in solid tumors (Table 2) -- CD73-adenosine -- CD155-TIGIT -- NKG2A -- Genetic engineering of NK cells -- Antigen escape and multitargeting CARs -- NK cell engagers -- Conclusions -- References -- Chapter 4: Targeting NKG2D/NKG2D ligand axis for cancer immunotherapy -- Introduction -- NKG2D -- Molecular characteristics and signaling -- NKG2D ligands -- Human NKG2D ligands. , Mouse NKG2D ligands -- Regulation of NKG2D ligands expression -- Transcriptional regulation -- Posttranslational regulation -- NKG2D in antitumor immunity -- NKG2D ligands stimulate tumor immunity -- Human tumors shed NKG2D ligands to evade immune response -- Strategies to harness NKG2D/NKG2DL for cancer immunotherapy -- Targeting MIC shedding to sustain NKG2D immunity -- Conclusions -- References -- Chapter 5: Chimeric antigen receptor-modified cells for the treatment of solid tumors: First steps in a thousand-m -- Introduction -- CAR T-cell therapy experience in solid tumors -- Glioblastoma -- Neuroblastoma -- Lung cancer -- Mesothelioma -- Breast cancer -- Ovarian cancer -- Prostate cancer -- Renal cell carcinoma -- Sarcoma -- Overcoming challenges facing CAR therapy in solid tumors -- Tumor microenvironment -- Nutrient deprivation -- Immunosuppressive substances -- Acidity -- Hypoxia -- Cell-mediated immunosuppression -- Prospects -- Extracellular matrix barrier -- Prospects -- CAR-T cell trafficking -- Prospects -- CAR T-cell persistence -- Prospects -- Target antigens -- Prospects -- Beyond CAR T-cell therapy -- Conclusion -- Acknowledgments -- References -- Chapter 6: Tumor-infiltrating lymphocyte (TIL) therapy -- Introduction -- Cytotoxic T lymphocytes mediate antigen-specific antitumor immunity -- Tumor immune evasion and T cell exhaustion -- Antigen nonspecific T cell immunotherapy approaches -- Adoptive cell therapy with autologous TILs (TIL ACT) -- Alteration of the immune tumor microenvironment to improves the engraftment of autologous TILs -- Improving antitumor efficacy of TIL ACT by targeting neoantigens -- Impact of cellular phenotype upon TIL ACT longevity -- Improvement in TIL manufacturing and modern-day clinical trials -- TILs and solid tumors other than melanoma -- Summary -- Acknowledgments -- References. , Chapter 7: Biology and status of chimeric antigen receptor-engineered T cell therapy -- Introduction -- Generations of CAR T cells -- FDA approved CAR T cells in hematologic malignancies -- Challenges in solid tumor targeting with CAR T cell therapy -- Physical and metabolic barriers in the solid tumor microenvironment -- The immunosuppressive TME -- Solid tumor antigen heterogeneity and antigen escape -- Future perspective of CAR T cell therapy approaches to tackle solid tumors -- References -- Section II: Process and trials optimization: Diagnostics, readouts, route, and production to optimize cell therapy -- Chapter 8: Optimization of production for cell therapies -- Keep the end goal in mind from early stage: Define the target product profile -- Process design: Take a quality by design approach -- Get to the goal: Many decisions to make -- Upstream processing -- Downstream processing -- Filling and cryopreservation -- Understand the analytical needs -- Identify and overcome the distribution, thawing, and dispensing challenges -- Conclusion -- References -- Chapter 9: Lymphodepletion and cellular immunotherapy -- Introduction -- Regimens for lymphodepletion -- Tumor-infiltrating lymphocytes (TILs) -- Chimeric antigen receptor T-cells (CAR-T cells) -- Solid tumors -- Toxicity of lymphodepletion -- Alternatives to lymphodepletion -- Conclusion -- References -- Chapter 10: Imaging the immune cell in immunotherapy -- Imaging objectives from an immunological perspective -- Imaging modalities and labeling strategies for cancer immunotherapy -- Optical imaging (OI) -- Fluorescence imaging (FLI) -- Bioluminescence imaging (BLI) -- Considerations for optical imaging -- Ultrasound imaging (US) -- Encapsulated gas microbubbles -- Nonmicrobubble contrast agents -- Considerations for ultrasound imaging -- Magnetic resonance imaging (MRI). , Negative contrast agents -- Nuclear-based imaging -- Basic principles of direct labeling -- Considerations for direct labeling -- Basic principles of indirect labeling with reporter genes -- Considerations for indirect labeling -- Application of the ``Imaging Toolbox´´ toward cancer immunotherapy -- Imaging T cell trafficking and persistence -- Imaging cytolytic T cells (CTLs) -- Imaging chimeric antigen receptor T (CAR-T) cells -- Imaging T cell activation -- Direct imaging T cell activation biomarkers -- Direct imaging of targets related to T cell activation and effector function -- Indirect imaging NFAT-mediated T cell activation -- Imaging metabolic targets -- Imaging the tumor microenvironment (TME) -- Imaging of programmed cell death protein 1 (PD-1/CD279) -- Imaging of programmed cell death protein ligand 1 (PD-L1/CD274) -- Imaging of cytotoxic T lymphocyte-associated protein 4 (CTLA-4/CD152) -- Imaging of lymphocyte activation gene 3 protein (LAG3) -- Imaging of T cell immunoglobulin and mucin domain-containing protein 3 (TIM3) -- Imaging of T cell immunoreceptor with Ig and ITIM domains (TIGIT) -- Imaging regulatory T cells (Tregs) -- Imaging NK cells -- Imaging dendritic cell vaccines -- What the future holds -- Acknowledgments -- References -- Chapter 11: Radiologic assessment of tumor response to immunotherapy and its complications -- Introduction -- Uses of medical imaging in immunotherapy -- Challenges to medical imaging presented by immunotherapy -- Unconventional patterns of response in immunotherapy -- Pseudo progression -- Hyperprogression -- Dissociated response -- Immune-related adverse events -- Immune checkpoint inhibitors -- CAR T cell therapies -- Methods of measurement of tumor response -- Conventional tumor response criteria -- Immune tumor response criteria -- FDG-PET for assessment of CAR T-cell therapy. , Future directions for imaging tumor response to immunotherapy.

Weitere Ausg.: Print version: Jewett, Anahid NK Cells in Cancer Immunotherapy: Successes and Challenges San Diego : Elsevier Science & Technology,c2022 ISBN 9780128226209

Sprache: Englisch

UID:

Umfang: 1 online resource (496 pages)

ISBN: 0-12-822626-9

Serie: Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy ; v.Volume 4

Inhalt: NK Cells in Cancer Immunotherapy: Successes and Challenges explains the latest immunotherapeutic strategies, focusing on NK cells to allow the best and precise combination treatments to cancer patients. The book provides existing background knowledge in the field of immunotherapy and discusses future areas of research required to carry out cutting-edge, validated therapies. Chapters cover advances in immunotherapeutic strategies, in particular, the use of NK cells with and without T-cell therapy in the treatment of cancer. The book is a valuable resource for cancer researchers, oncologists, graduate students and those interested in learning more about novel strategies to treat cancer patients.

Anmerkung: Intro -- NK Cells in Cancer Immunotherapy: Successes and Challenges -- Copyright -- Cover Image Insert -- Hypothetical role of NK cells in differentiation of tumor cells, increased susceptibility of tumor cells to chemotherapy or ... -- Aims and Scope of Series ``Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy´´ -- About the Series Editor -- Aims and Scope of Volume -- About the Volume Editors -- Preface-Cellular immunotherapies: Evolution from laboratory studies to effective human therapies -- Contents -- Contributors -- Section I: Basics of cellular immunotherapy: Differing roles of NK and T cells in targeting cancer and their intimate syn ... -- Chapter 1: Multifaceted nature of natural killer cells: Potential mode of interaction and shaping of stem cells -- Natural killer cells: Overview and background -- Two faces of NK cells: Concept of split anergy in NK cells and its potential role in tumor differentiation -- The rationale for the functional activation of NK cells in many gene knockout mice: Potential common mechanism of activation -- Dysfunctional NK cells in cancer patients: Defects in NK cells to lyse and differentiate CSCs -- Suppression of antitumor immune function and change in NK cell phenotype in tumor microenvironment: Could compromised NK fu ... -- Tumor-associated stromal cells may shape the function of NK cells -- Function of NK cells in tumor-bearing humanized-BLT mice mirrors those of the cancer patients -- Novel strategy to expand supercharged NK cells for immunotherapy using osteoclasts as feeder cells: Different efficacy of s ... -- Supercharged NK cells differ from primary NK cells in phenotype and function -- Supercharged NK cells preferentially and rapidly expand CD8+ T cells -- Functional differences of NK cells in different NK expansion platforms against CSCs/poorly differentiated tumor cells: Comp. , Immunotherapy is essential in combination with chemotherapy: Chemotherapy targets differentiated tumors more than cancer st ... -- Combination of NK cell and antibody therapy: NK cells can target CSCs and their differentiated counterparts through direct ... -- NK cells and the oncolytic viruses -- Combination therapy with NK cells and immune checkpoint inhibitors -- Conclusions -- Acknowledgments -- References -- Chapter 2: Reversing the NK inhibitory tumor microenvironment by targeting suppressive immune effectors -- Introduction -- Dysregulation of NK cell immune responses by the tumor microenvironment -- Suppressive immune effectors of the tumor microenvironment -- Myeloid-derived suppressor cells -- Tumor-associated macrophages -- Regulatory T cells -- Dendritic cells -- Techniques to evaluate the tumor microenvironment -- Improvements in tissue analysis and imaging -- Cytometric analysis of TME composition and function -- Estimating TME composition using gene expression data -- Assessing metabolic fitness in the TME -- Advancements in therapeutic modalities to overcome TME suppression -- Direct targeting of inhibitory immune cells of the TME -- Reversing NK cell inhibition by the TME through genetic and nongenetic methods -- Perspectives and conclusions -- References -- Chapter 3: Natural killer cells as immunotherapeutic effectors for solid tumors -- Introduction -- Sources of NK cells for immunotherapy (Table 1) -- Expanding NK cells -- Challenges to NK cell immunotherapy in solid tumors (Table 2) -- CD73-adenosine -- CD155-TIGIT -- NKG2A -- Genetic engineering of NK cells -- Antigen escape and multitargeting CARs -- NK cell engagers -- Conclusions -- References -- Chapter 4: Targeting NKG2D/NKG2D ligand axis for cancer immunotherapy -- Introduction -- NKG2D -- Molecular characteristics and signaling -- NKG2D ligands -- Human NKG2D ligands. , Mouse NKG2D ligands -- Regulation of NKG2D ligands expression -- Transcriptional regulation -- Posttranslational regulation -- NKG2D in antitumor immunity -- NKG2D ligands stimulate tumor immunity -- Human tumors shed NKG2D ligands to evade immune response -- Strategies to harness NKG2D/NKG2DL for cancer immunotherapy -- Targeting MIC shedding to sustain NKG2D immunity -- Conclusions -- References -- Chapter 5: Chimeric antigen receptor-modified cells for the treatment of solid tumors: First steps in a thousand-m -- Introduction -- CAR T-cell therapy experience in solid tumors -- Glioblastoma -- Neuroblastoma -- Lung cancer -- Mesothelioma -- Breast cancer -- Ovarian cancer -- Prostate cancer -- Renal cell carcinoma -- Sarcoma -- Overcoming challenges facing CAR therapy in solid tumors -- Tumor microenvironment -- Nutrient deprivation -- Immunosuppressive substances -- Acidity -- Hypoxia -- Cell-mediated immunosuppression -- Prospects -- Extracellular matrix barrier -- Prospects -- CAR-T cell trafficking -- Prospects -- CAR T-cell persistence -- Prospects -- Target antigens -- Prospects -- Beyond CAR T-cell therapy -- Conclusion -- Acknowledgments -- References -- Chapter 6: Tumor-infiltrating lymphocyte (TIL) therapy -- Introduction -- Cytotoxic T lymphocytes mediate antigen-specific antitumor immunity -- Tumor immune evasion and T cell exhaustion -- Antigen nonspecific T cell immunotherapy approaches -- Adoptive cell therapy with autologous TILs (TIL ACT) -- Alteration of the immune tumor microenvironment to improves the engraftment of autologous TILs -- Improving antitumor efficacy of TIL ACT by targeting neoantigens -- Impact of cellular phenotype upon TIL ACT longevity -- Improvement in TIL manufacturing and modern-day clinical trials -- TILs and solid tumors other than melanoma -- Summary -- Acknowledgments -- References. , Chapter 7: Biology and status of chimeric antigen receptor-engineered T cell therapy -- Introduction -- Generations of CAR T cells -- FDA approved CAR T cells in hematologic malignancies -- Challenges in solid tumor targeting with CAR T cell therapy -- Physical and metabolic barriers in the solid tumor microenvironment -- The immunosuppressive TME -- Solid tumor antigen heterogeneity and antigen escape -- Future perspective of CAR T cell therapy approaches to tackle solid tumors -- References -- Section II: Process and trials optimization: Diagnostics, readouts, route, and production to optimize cell therapy -- Chapter 8: Optimization of production for cell therapies -- Keep the end goal in mind from early stage: Define the target product profile -- Process design: Take a quality by design approach -- Get to the goal: Many decisions to make -- Upstream processing -- Downstream processing -- Filling and cryopreservation -- Understand the analytical needs -- Identify and overcome the distribution, thawing, and dispensing challenges -- Conclusion -- References -- Chapter 9: Lymphodepletion and cellular immunotherapy -- Introduction -- Regimens for lymphodepletion -- Tumor-infiltrating lymphocytes (TILs) -- Chimeric antigen receptor T-cells (CAR-T cells) -- Solid tumors -- Toxicity of lymphodepletion -- Alternatives to lymphodepletion -- Conclusion -- References -- Chapter 10: Imaging the immune cell in immunotherapy -- Imaging objectives from an immunological perspective -- Imaging modalities and labeling strategies for cancer immunotherapy -- Optical imaging (OI) -- Fluorescence imaging (FLI) -- Bioluminescence imaging (BLI) -- Considerations for optical imaging -- Ultrasound imaging (US) -- Encapsulated gas microbubbles -- Nonmicrobubble contrast agents -- Considerations for ultrasound imaging -- Magnetic resonance imaging (MRI). , Negative contrast agents -- Nuclear-based imaging -- Basic principles of direct labeling -- Considerations for direct labeling -- Basic principles of indirect labeling with reporter genes -- Considerations for indirect labeling -- Application of the ``Imaging Toolbox´´ toward cancer immunotherapy -- Imaging T cell trafficking and persistence -- Imaging cytolytic T cells (CTLs) -- Imaging chimeric antigen receptor T (CAR-T) cells -- Imaging T cell activation -- Direct imaging T cell activation biomarkers -- Direct imaging of targets related to T cell activation and effector function -- Indirect imaging NFAT-mediated T cell activation -- Imaging metabolic targets -- Imaging the tumor microenvironment (TME) -- Imaging of programmed cell death protein 1 (PD-1/CD279) -- Imaging of programmed cell death protein ligand 1 (PD-L1/CD274) -- Imaging of cytotoxic T lymphocyte-associated protein 4 (CTLA-4/CD152) -- Imaging of lymphocyte activation gene 3 protein (LAG3) -- Imaging of T cell immunoglobulin and mucin domain-containing protein 3 (TIM3) -- Imaging of T cell immunoreceptor with Ig and ITIM domains (TIGIT) -- Imaging regulatory T cells (Tregs) -- Imaging NK cells -- Imaging dendritic cell vaccines -- What the future holds -- Acknowledgments -- References -- Chapter 11: Radiologic assessment of tumor response to immunotherapy and its complications -- Introduction -- Uses of medical imaging in immunotherapy -- Challenges to medical imaging presented by immunotherapy -- Unconventional patterns of response in immunotherapy -- Pseudo progression -- Hyperprogression -- Dissociated response -- Immune-related adverse events -- Immune checkpoint inhibitors -- CAR T cell therapies -- Methods of measurement of tumor response -- Conventional tumor response criteria -- Immune tumor response criteria -- FDG-PET for assessment of CAR T-cell therapy. , Future directions for imaging tumor response to immunotherapy.

Weitere Ausg.: Print version: Jewett, Anahid NK Cells in Cancer Immunotherapy: Successes and Challenges San Diego : Elsevier Science & Technology,c2022 ISBN 9780128226209

Sprache: Englisch